Article Text

PDF
rRNA-based tests for chlamydial infection in trachoma
  1. Robin Bailey
  1. Correspondence to: Robin Bailey London School of Hygiene & Tropical Medicine Keppel Street, London WC1E 7HT, UK; robin.bailey{at}lshtm.ac.uk

Statistics from Altmetric.com

Trachoma, the worlds leading cause of preventable blindness, is the subject of worldwide control efforts via the SAFE (Surgery, Antibiotic Treatment, Facial Cleanliness and Environmental Improvement) strategy. The “A” component of this strategy antibiotic treatment of the active disease has been supported through the large scale donation of millions of doses of the antibiotic azithromycin by its manufacturers, Pfizer, for distribution in trachoma endemic areas by the International Trachoma Initiative.1 Azithromycin, as a single 20 mg/kg oral dose is effective against Chlamydia trachomatis infection.2 In the field the diagnosis of active trachoma may be made simply by examining the surface of the everted upper eyelid for clinical signs of trachoma: lymphoid follicles and inflammatory thickening.3 Current recommendations …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles